AU2008289653B2 - MIPO inhibitors for the treatment of Huntington's disease and multiple system atrophy - Google Patents

MIPO inhibitors for the treatment of Huntington's disease and multiple system atrophy Download PDF

Info

Publication number
AU2008289653B2
AU2008289653B2 AU2008289653A AU2008289653A AU2008289653B2 AU 2008289653 B2 AU2008289653 B2 AU 2008289653B2 AU 2008289653 A AU2008289653 A AU 2008289653A AU 2008289653 A AU2008289653 A AU 2008289653A AU 2008289653 B2 AU2008289653 B2 AU 2008289653B2
Authority
AU
Australia
Prior art keywords
thioxo
tetrahydro
methyl
purin
mpo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008289653A
Other languages
English (en)
Other versions
AU2008289653A1 (en
Inventor
Hakan Eriksson
Werner Poewe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2008289653A1 publication Critical patent/AU2008289653A1/en
Application granted granted Critical
Publication of AU2008289653B2 publication Critical patent/AU2008289653B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2008289653A 2007-08-23 2008-08-22 MIPO inhibitors for the treatment of Huntington's disease and multiple system atrophy Ceased AU2008289653B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95752307P 2007-08-23 2007-08-23
US95752507P 2007-08-23 2007-08-23
US60/957,523 2007-08-23
US60/957,525 2007-08-23
PCT/SE2008/050950 WO2009025618A1 (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Publications (2)

Publication Number Publication Date
AU2008289653A1 AU2008289653A1 (en) 2009-02-26
AU2008289653B2 true AU2008289653B2 (en) 2012-06-28

Family

ID=40378392

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008289653A Ceased AU2008289653B2 (en) 2007-08-23 2008-08-22 MIPO inhibitors for the treatment of Huntington's disease and multiple system atrophy

Country Status (25)

Country Link
US (6) US20090054468A1 (enExample)
EP (1) EP2200616B1 (enExample)
JP (2) JP5247804B2 (enExample)
KR (1) KR101588464B1 (enExample)
CN (4) CN105687199A (enExample)
AU (1) AU2008289653B2 (enExample)
BR (1) BRPI0815681A2 (enExample)
CA (1) CA2698205C (enExample)
CY (1) CY1113714T1 (enExample)
DK (1) DK2200616T3 (enExample)
EA (1) EA017510B1 (enExample)
ES (1) ES2399846T3 (enExample)
HR (1) HRP20130139T1 (enExample)
IL (2) IL203738A (enExample)
ME (1) ME01510B (enExample)
MX (1) MX2010001983A (enExample)
MY (1) MY155633A (enExample)
NZ (1) NZ584135A (enExample)
PH (1) PH12014501180A1 (enExample)
PL (1) PL2200616T3 (enExample)
PT (1) PT2200616E (enExample)
RS (1) RS52665B (enExample)
SI (1) SI2200616T1 (enExample)
WO (1) WO2009025618A1 (enExample)
ZA (1) ZA201000848B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
BR112014011254A2 (pt) 2011-11-11 2017-05-16 Pfizer 2-tiopirimidinonas
ES2587954T3 (es) * 2012-03-29 2016-10-27 Basf Se Compuestos de hetero-bicíclicos N-sustituidos y derivados para combatir plagas animales II
US9616063B2 (en) 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
AU2016257179A1 (en) 2015-05-05 2017-11-02 Pfizer Inc. 2-thiopyrimidinones
BR112019027717A2 (pt) * 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
KR102705858B1 (ko) * 2017-07-17 2024-09-10 아스트라제네카 아베 의약에서의 사용을 위한 mpo 억제제
EP4041735A4 (en) * 2019-10-10 2023-11-22 Biohaven Therapeutics Ltd. MYELOPEROXIDASE INHIBITOR PRODRUGS
AU2021230370A1 (en) * 2020-03-05 2022-10-20 Biohaven Therapeutics Ltd. Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor
CN115551511A (zh) * 2020-05-06 2022-12-30 拜尔哈文制药股份有限公司 用于制备维迪泊司他的方法
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
EP4573096A1 (en) 2022-08-18 2025-06-25 Astrazeneca AB Inhibitors of myeloperoxidase
WO2024047094A1 (en) * 2022-08-31 2024-03-07 Astrazeneca Ab Pharmaceutical formulation
WO2024120457A1 (zh) * 2022-12-09 2024-06-13 深圳信立泰药业股份有限公司 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途
WO2024163892A1 (en) * 2023-02-02 2024-08-08 University Of Virginia Patent Foundation Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah)
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089430A1 (en) * 2002-04-19 2003-10-30 Astrazeneca Ab Thioxanthine derivatives as myeloperoxidase inhibitors
WO2006062465A1 (en) * 2004-12-06 2006-06-15 Astrazeneca Ab Novel pyrrolo [3, 2-d] pyrimidin-4-one derivatives and their use in therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE325610T1 (de) * 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
MXPA04007299A (es) * 2002-01-28 2004-10-29 Kyowa Hakko Kogyo Kk Metodos de tratamiento de pacientes que sufren de trastornos de movimiento.
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
US20090124640A1 (en) * 2006-06-05 2009-05-14 Astrazeneca Ab Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089430A1 (en) * 2002-04-19 2003-10-30 Astrazeneca Ab Thioxanthine derivatives as myeloperoxidase inhibitors
WO2006062465A1 (en) * 2004-12-06 2006-06-15 Astrazeneca Ab Novel pyrrolo [3, 2-d] pyrimidin-4-one derivatives and their use in therapy

Also Published As

Publication number Publication date
DK2200616T3 (da) 2013-03-04
CN101873857A (zh) 2010-10-27
CN113633641A (zh) 2021-11-12
CN105687199A (zh) 2016-06-22
US20200405724A1 (en) 2020-12-31
PH12014501180A1 (en) 2015-08-24
JP2010536849A (ja) 2010-12-02
EP2200616A1 (en) 2010-06-30
US20130059870A1 (en) 2013-03-07
IL203738A (en) 2015-08-31
EA017510B1 (ru) 2013-01-30
ME01510B (me) 2014-04-20
HK1145141A1 (en) 2011-04-08
EP2200616B1 (en) 2012-12-26
US20110207755A1 (en) 2011-08-25
ZA201000848B (en) 2012-07-25
EA201000202A1 (ru) 2010-10-29
RS52665B (sr) 2013-06-28
CY1113714T1 (el) 2016-06-22
JP2013151547A (ja) 2013-08-08
US20190099423A1 (en) 2019-04-04
PL2200616T3 (pl) 2013-04-30
MX2010001983A (es) 2010-03-10
WO2009025618A1 (en) 2009-02-26
AU2008289653A1 (en) 2009-02-26
US20090054468A1 (en) 2009-02-26
CA2698205A1 (en) 2009-02-26
MY155633A (en) 2015-11-13
CN103638029A (zh) 2014-03-19
EP2200616A4 (en) 2010-08-25
PT2200616E (pt) 2013-02-27
BRPI0815681A2 (pt) 2015-02-18
HRP20130139T1 (hr) 2013-03-31
NZ584135A (en) 2012-04-27
KR20100055434A (ko) 2010-05-26
ES2399846T3 (es) 2013-04-03
CA2698205C (en) 2016-06-21
IL240130A0 (en) 2015-09-24
US20140221400A1 (en) 2014-08-07
SI2200616T1 (sl) 2013-03-29
JP5247804B2 (ja) 2013-07-24
KR101588464B1 (ko) 2016-01-25
US10772890B2 (en) 2020-09-15

Similar Documents

Publication Publication Date Title
US10772890B2 (en) Use of myeloperoxidase (MPO) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (MSA) 938
JP6811203B2 (ja) 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
Liou et al. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor
US8592420B2 (en) Method of treating an anxiety disorder
WO1999026627A1 (en) (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
EP2355657A1 (en) Compositions and methods of treating endothelial disorders
US20090053176A1 (en) New Combination 937
US11103479B2 (en) Small organic molecules for use in the treatment of neuroinflammatory disorders
US20120094985A1 (en) Pharmaceutical compositions comprising chlorophenyl piperazine derived compounds and use of the compounds in producing medicaments
HK1145141B (en) Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy
Lapin et al. Antiethanol effects of indol-3-ylpyruvic acid in mice
CN120346202A (zh) Ripk1抑制剂及其在治疗神经功能障碍中的用途
CN118742301A (zh) 用于治疗或预防衰老相关病症的苯并二氢吡喃醇化合物
BRPI0920699A2 (pt) uso de um inibidor de dpp-4 no tratamento de diabetes em pacientes com controle insuficiente da glicemia apesar de terapia com um fármaco antidiabético oral ou não-oral
US20110046141A1 (en) Use of pde5 inhibitors for treating circadian rhythm disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired